In a sign that its pipeline strategy might be shifting, Thousand Oaks-based Amgen has paired up with one of the most prominent venture capital firms in Silicon Valley to start a new company to develop six of its drug ideas. Atara Biotherapeutics will be financed by Kleiner Perkins Caufield & Byers, which will retain a…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
